Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with Anti-EGFR therapy

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 1087-1097

  Laurent Puig, Pierre ^a,b   Pekin, Deniz ^a   Normand, Corinne ^a   Kotsopoulos, Steve K ^c   Nizard, Philippe ^a   Perez Toralla, Karla ^a   Rowell, Rachel ^c   Olson, Jeff ^c   Srinivasan, Preethi ^c   Le Corre, Delphine ^a   Hor, Thevy ^a   El Harrak, Zakaria ^a   Li, Xinyu ^c   Link, Darren R ^c   Bouche, Olivier ^d   Emile, Jean Francois ^e   Landi, Bruno ^b   Boige, Valerie ^f   Hutchison, J Brian ^c   Taly, Valerie ^a  

^a Centre Universitaire des Saints Pères   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c RainDance Technologies   (United States)

^d SERVICE DE DERMATOLOGIE   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAF GENE; CLINICAL ARTICLE; CLONE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PICODROPLET DIGITAL POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE POLYMERASE CHAIN REACTION; WILD TYPE; ALLELE; ANTAGONISTS AND INHIBITORS; CANCER STAGING; COLORECTAL NEOPLASMS; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; RETREATMENT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT; TREATMENT OUTCOME;

EID: 84929463919     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0983     Document Type: Article

References (38)

1. Tougeron D, Lecomte T, Pages JC, Villalva C, Collin C, Ferru A, et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 2013; 24: 1267-73.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-9.
4. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-7.
5. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-9.
6. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-15.
7. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-72.
8. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapyinwild-type KRAS metastatic colon cancer. JClin Oncol 2009; 27: 5924-30.
9. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol Hematol 2013; 85: 45-81.
10. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-34.
11. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-40.
12. Oltedal S, Aasprong OG, Moller JH, Korner H, Gilje B, Tjensvoll K, et al. Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. Int J Colorectal Dis 2011; 26: 1271-7.
13. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008; 453: 417-31.
14. Carotenuto P, Roma C, Rachiglio AM, Tatangelo F, Pinto C, Ciardiello F, et al. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 2010; 11: 1169-79.
15. Dufort S, Richard MJ, de Fraipont F. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem 2009; 391: 166-8.
16. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005; 7: 413-21.
17. Angulo B, Garcia-Garcia E, Martinez R, Suarez-Gauthier A, Conde E, Hidalgo M, et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 2010; 12: 292-9.
18. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 2010; 12: 425-32.
19. Taly V, Pekin D, Abed AE, Laurent-Puig P. Detecting biomarkers with microdroplet technology. Trends Mol Med 2012; 18: 405-16.
20. Pekin D, Skhiri Y, Baret JC, Le Corre D, Mazutis L, Ben Salem C, et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. Lab Chip 2011: 2156-66.
21. Pinheiro L, Emslie KR, Hindson BJ, Hindson C, Herrmann J, Coleman VA, et al. Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification. Anal Chem 2012; 84: 1003-11.
22. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011; 83: 8604-10.
23. Hatch AC, Fisher JS, Tovar AR, Hsieh AT, Lin R, Pentoney SL, et al. 1-Million droplet array with wide-field fluorescence imaging for digital PCR. Lab Chip 2011; 11: 3838-45.
24. Zhong Q, Bhattacharya S, Kotsopoulos S, Olson J, Taly V, Griffiths AD, et al. Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR. Lab Chip 2011; 11: 2167-74.
25. Didelot A, Kotsopoulos SK, Lupo A, Pekin D, Li X, Atochin I, et al. Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples. Clin Chem 2013; 59: 815-23.
26. Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 2013; 59: 1722-31.
27. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-6.
28. Di Fiore F, Le Pessot F, Blanchard F, Charbonnier F, Lamy A, Frebourg T, et al. Clinical relevance of kras mutation detection in metastatic colorectal cancer treated by cetuximala plus chemotherapy. Gastroenterology 2007; 132:A433-A.
29. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011; 17: 4901-14.
30. Bando H, Yoshino T, Tsuchihara K, Ogasawara N, Fuse N, Kojima T, et al. KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br J Cancer 2011; 105: 403-6.
31. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005; 102: 16368-73.
32. Diehl F, Schmidt K, Durkee KH, Moore KJ, Goodman SN, Shuber AP, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 2008; 135: 489-98.
33. Heredia NJ, Belgrader P, Wang S, Koehler R, Regan J, Cosman AM, et al. Droplet Digital PCR quantitation of HER2 expression in FFPE breast cancer samples. Methods 2013; 59:S20-3.
34. Diehl F, Diaz LA Jr Digital quantification of mutant DNA in cancer patients. Curr Opin Oncol 2007; 19: 36-42.
35. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A 1999; 96: 9236-41.
36. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013; 10: 472-84.
37. Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, et al. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011; 16: 467-78.
38. Diehl P. Getting at the underlying causes of cancer. Molecular analysis of tumors to improve characterization and treatment. 2013. Available from: http://biotech.about.com/od/technicaltheory/a/Getting-At-The-Underlying-Causes-Of-Cancer.html.